Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

Combining bevacizumab with erlotinib shrinks tumors in patients with rare and aggressive kidney cancer

Seventy-two percent of patients with HLRCC-associated kidney cancers, for which there previously was no known drug treatment, responded to the therapy in a clinical trial.

Clinical trial researches bone marrow transplants for blood cancers

A clinical trial led by Christopher G. Kanakry, M.D., Lasker Clinical Research Scholar in the Center for Immuno-Oncology, is researching bone marrow transplants for some types of blood cancers, such as high-risk leukemia, lymphoma, myelodysplastic syndrome or multiple myeloma.

CCR Hosts Communications Course for Healthcare Providers in Oncology

Dedicated transdisciplinary teams of healthcare providers from the CCR’s Clinical Care Programs gathered to learn communication skills centered on essential topics of patient care.

A stain of HPV-negative head and neck squamous cell carcinoma that has high levels of SMYD3

Chromatin modifier linked to immunotherapy resistance in HPV-negative head and neck cancers

Researchers have discovered that a chromatin-regulating enzyme called SMYD3 limits the access of cancer-attacking immune cells to HPV-negative head and neck cancers, therefore decreasing immunotherapy’s effectiveness. Depleting SMYD3 increased the cancer’s sensitivity to a standard immunotherapy drug in mouse models.

New insights explain how the same protein can serve different functions

Proteins can often choose between potential interacting partners and serve different functions inside cells. How these choices are made is not entirely clear. New research shows that the exact location in a cell where the protein is produced and the rate of its synthesis are key factors in this choice.

New T-cell therapy shrinks solid tumors in early-phase clinical trial

Trial results show that engineered T cells can effectively target mesothelin, a protein found on many solid tumors.

Studies of an experimental ovarian cancer therapy identify a biomarker of treatment response

A new biomarker may identify patients who can benefit from drugs that inhibit CHK1 after their ovarian cancer has become resistant to PARP inhibitors.

Remembering Miranda Leah Hanson-Baseler, an indomitable immunologist

Faced with a uterine sarcoma diagnosis at just 24, Miranda Leah Hanson-Baseler persevered through treatments for 17 years.

New analysis reveals potential effective drug combinations for treating lung cancer

Researchers compared more than 5,000 drug combinations in lung cancer cells, the results of which point to combinations that may be particularly effective in combating cancer in humans.

Cells’ decision to divide is reversible

Surprising findings show that cells that are preparing to divide can return to a resting state if they lose growth signals, even after they have passed what was previously thought to be a point of no return.

Drug combination provides a one-two punch attack against colorectal cancer

Researchers have identified a drug that, when combined with TOP1 inhibitors, results in improved efficacy in human colorectal cancer models — a finding that may apply to other cancers treated with TOP1 inhibitors. The results also yield important insights into our basic understanding of DNA replication and repair.

Breadcrumb

News and Events